ScreenerHero
HomeScreenerChartsCompareGroupsMapsCommoditiesWatchlists·PricingBlog
Create free account
Sign in
ScreenerHero

The most complete stock screener for serious investors. 18,000+ stocks across US, Canada, Europe & Australia.

All systems operational
Tools
  • Screener
  • Maps
  • Commodities
  • Charts
  • Watchlists
  • Alerts
  • Calendar
  • Portfolio
Screeners
  • US & Canada
  • Nordic
  • Benelux
  • Dividend EU
  • Value EU
  • Microcap EU
  • Small Cap EU
  • Investor screens
Compare
  • vs Stockopedia
  • vs Finviz
  • vs Koyfin
  • vs TradingView
  • All comparisons
  • Alternatives
Company
  • About
  • Coverage
  • Blog
  • Help
  • Pricing
  • Affiliate Program
  • Terms of Service
  • Privacy Policy
Screeners by countryUKGermanyFranceSpainItalyNetherlandsSwitzerlandSwedenNorwayDenmarkFinlandBelgiumAustriaPortugalPolandGreeceTurkeyRomaniaCanadaMexicoAustraliaNew Zealand
Deutsch·Français·Español·Italiano

For informational and educational purposes only. Not financial advice. Market participation involves substantial risk of loss. Past performance does not guarantee future results. Always do your own research.

© 2026 ScreenerHero.com · All rights reserved
ScreenerHero

ANRO Alto Neuroscience, Inc.

NYSE · US · Healthcare · Biotechnology · altoneuroscience.com
25.37USD-4.30%Mkt Cap: 1.02B USDP/E: —2d ago

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.…

ANROAlto Neuroscience, Inc.
25.37USD-4.30%

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$130.58BUSDP/E 33.1
REGN
Regeneron Pharmaceuticals, Inc.
$95.24BUSDP/E 20.4
MRNA
Moderna, Inc.
$78.90BUSD
CSL
CSL Limited
$63.11BUSD
ARGX
argenx SE
$58.94BUSDP/E 34.3
UCB
UCB SA
$58.59BUSDP/E 24.7
ARGX
argenx SE
$58.21BUSDP/E 32.1
ONC
BeOne Medicines AG
$44.66BUSDP/E 50.1
RPRX
Royalty Pharma plc
$39.36BUSDP/E 44.7
RVMD
Revolution Medicines, Inc.
$34.87BUSD
GMAB
Genmab A/S
$31.45BUSDP/E 46.1
GMAB
Genmab A/S
$31.20BUSDP/E 42.9
INSM
Insmed Incorporated
$31.01BUSD
ROIV
Roivant Sciences Ltd.
$28.01BUSD
INCY
Incyte Corporation
$23.36BUSDP/E 58.5
BNTX
BioNTech SE
$20.07BUSD
ALNY
Alnylam Pharmaceuticals, Inc.
$19.26BUSDP/E 7.3
ASND
Ascendis Pharma A/S
$16.58BUSDP/E 17.6
EXEL
Exelixis, Inc.
$15.77BUSDP/E 19.4
BBIO
BridgeBio Pharma, Inc.
$14.81BUSD
Institutional holders20 on file

Key Statistics

Company
Market Cap1.02B USD
Enterprise Value762.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.24M USD
Revenue/Share—
Last Price25.37 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.58
PEG—
EV/EBITDA-7.63
EV/Revenue—
P/S—
P/B3.42
EPS (TTM)-2.32 USD
EPS (Forward)-2.96 USD
52W Range
10.8055% of range37.43
52W High37.43 USD
52W Low10.80 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.84%
ROA-34.24%
ROIC—
ROCE-38.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.77M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-4.95%
Net Debt-301.32M USD
Net Debt/EBITDA3.02
Net Debt/FCF—
Balance Sheet
Debt/Equity0.16
Current Ratio18.12
Quick Ratio17.90
Book Value/Sh7.42 USD
Cash/Share7.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.67 USD
Upside (mean)+52.4%
Target Range26.00 USD – 60.00 USD
26.00+52.4% to mean60.00
# Analysts9
Ownership
Shares Out.40.11M
Float30.46M
Insiders4.12%
Institutions103.28%
Short Interest
Short Ratio9.0d
Short % Float16.60%
Short % Out.14.22%
Shares Short5.68M
Short (prev mo.)4.66M
Technical
SMA 5025.82 (-1.7%)
SMA 20024.89 (+1.9%)
Beta1.45
S&P 52W Chg12.00%
Avg Vol (30d)658.86K
Avg Vol (10d)776.35K
Technical Indicators
RSI (14)48.6
MACD0.5114
MACD Signal0.4769
MACD Hist.+0.0344
BB Upper31.27 USD
BB Middle25.38 USD
BB Lower19.49 USD
BB Width46.43%
ATR (14)2.078 USD
Vol Ratio (20d)0.86x

Quality & Moat

23No Moat
Op. Margin0.0%
Net Margin0.0%
ROE-41.8%
D/E Ratio0.16

Recent News

All 11

Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?

Yahoo Finance·4d ago
  • Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know

    Yahoo Finance·6d ago
  • Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know

    Yahoo Finance·6d ago
  • Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts

    Proactive·Nov 11, 2026
  • Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights

    Yahoo Finance·Nov 10, 2026
  • Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value

    Yahoo Finance·Nov 10, 2026
  • Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

    Yahoo Finance·Nov 4, 2026
  • Alto Neuroscience Announces Participation in Upcoming Investor Conferences

    Yahoo Finance·Nov 3, 2026
  • Here's Why You Should Add ANRO Stock to Your Portfolio Now

    Yahoo Finance·Oct 14, 2026
  • Alto Neuroscience Announces Participation in Upcoming Investor Conferences

    Yahoo Finance·Sep 9, 2026
  • About Alto Neuroscience (NYSE: ANRO)

    ›

    Alto Neuroscience (NYSE: ANRO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 68 employees.

    The shares were at 25.37 USD on 20 November 2026, up 119.7% over 52 weeks. Its 52-week range is 10.80 USD to 37.43 USD: the price is 32.2% below the high and 134.9% above the low.

    Its market capitalisation is 1.02B USD.

    Alto Neuroscience reports return on equity of -41.8% and an operating margin of 0.0%.

    It holds more cash than debt, a net cash position of 301.32M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 38.67 USD is 52.4% above the current price. The next earnings report is expected on 15 March 2027.

    Compare ANRO with VRTX and REGN →

    Upcoming Events

    Next earnings
    2027-03-15(in 113 days)After close
    EPS est: -0.65
    Full calendar